A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate
  • Indications Joint disorders; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms LITHE
  • Sponsors Roche
  • Most Recent Events

    • 16 Jun 2018 Results determining the association of CXCL13 and sICAM1 with response to Tocilizumab and disease activity in early RA and DMARD IR patients subsets from the FUNCTION (early RA) and LITHE (DMARD IR) clinical trials presented at the 19th Annual Congress of the European League Against Rheumatism
    • 08 Nov 2017 Results of two phase III trials (NCT00106522 and NCT00106535) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top